• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.

作者信息

Scalzulli Emilia, Ielo Claudia, Luise Cristina, Musiu Paolo, Bisegna Maria L, Carmosino Ida, Assanto Giovanni M, Martelli Maurizio, Breccia Massimo

机构信息

Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.

出版信息

Blood Adv. 2022 Aug 9;6(15):4424-4426. doi: 10.1182/bloodadvances.2022008158.

DOI:10.1182/bloodadvances.2022008158
PMID:35737865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9636318/
Abstract
摘要

相似文献

1
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.RR6预后模型提供了关于芦可替尼治疗骨髓纤维化患者生存情况的信息：在真实队列中的验证
Blood Adv. 2022 Aug 9;6(15):4424-4426. doi: 10.1182/bloodadvances.2022008158.
2
Ruxolitinib: the first agent approved for myelofibrosis.芦可替尼：首个获批用于治疗骨髓纤维化的药物。
Clin Adv Hematol Oncol. 2012 Feb;10(2):111-3.
3
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.预测芦可替尼治疗骨髓纤维化患者 6 个月后生存的预后模型。
Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889.
4
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.芦可替尼对真实世界中骨髓纤维化患者生存的影响：ERNEST研究更新
Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006.
5
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.更新的芦可替尼治疗骨髓纤维化的使用建议。
Hematology. 2022 Dec;27(1):23-31. doi: 10.1080/16078454.2021.2009645.
6
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience.费拉替尼对每日两次服用20毫克或更高剂量芦可替尼后复发/难治的骨髓纤维化患者疗效有限：一项真实世界经验。
Br J Haematol. 2022 Aug;198(4):e54-e58. doi: 10.1111/bjh.18284. Epub 2022 May 25.
7
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.真实世界中接受芦可替尼治疗的骨髓纤维化患者的临床结局：病历回顾。
Future Oncol. 2022 Jun;18(18):2217-2231. doi: 10.2217/fon-2021-1358. Epub 2022 Apr 7.
8
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.在既往接受过鲁索替尼治疗的骨髓纤维化患者中使用Janus激酶2抑制剂非格司亭（JAKARTA-2）：一项单臂、开放标签、非随机、2期、多中心研究。
Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.
9
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.芦可替尼真的能延长骨髓纤维化患者的生存期吗？这是个没完没了的故事。
Blood Adv. 2022 Apr 12;6(7):2331-2333. doi: 10.1182/bloodadvances.2022007230.
10
Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.在原发性和继发性骨髓纤维化中，铁调素水平升高，并且在用鲁索替尼治疗的患者中仍保持升高。
Br J Haematol. 2022 May;197(4):e49-e52. doi: 10.1111/bjh.18044. Epub 2022 Feb 6.

引用本文的文献

1
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.芦可替尼治疗的中危-1风险骨髓纤维化患者的修订版“iRR6”模型
Cancer. 2025 Sep 1;131(17):e70062. doi: 10.1002/cncr.70062.
2
Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.芦可替尼治疗的骨髓纤维化患者异基因造血细胞移植的优化：入选标准、最佳实践及改善移植结局
Ann Hematol. 2025 Apr;104(4):2125-2141. doi: 10.1007/s00277-025-06270-9. Epub 2025 Mar 22.
3
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.

本文引用的文献

1
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.预测芦可替尼治疗骨髓纤维化患者 6 个月后生存的预后模型。
Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889.
2
How and When to Manage Ruxolitinib Failure in Myelofibrosis.骨髓纤维化中芦可替尼治疗失败时的处理方法及时机
JCO Oncol Pract. 2020 Jul;16(7):361-362. doi: 10.1200/OP.20.00079.
3
Management of myelofibrosis after ruxolitinib failure.芦可替尼治疗失败后的骨髓纤维化处理。
RR6模型用于预测芦可替尼治疗6个月后生存率的验证及分子整合
Haematologica. 2024 Oct 1;109(10):3398-3403. doi: 10.3324/haematol.2024.285098.
4
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.AIPSS-MF 机器学习预后评分在接受鲁索利替尼治疗的骨髓纤维化患者队列中的验证。
Cancer Rep (Hoboken). 2023 Oct;6(10):e1881. doi: 10.1002/cnr2.1881. Epub 2023 Aug 8.
5
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.骨髓纤维化与生存预后模型：过去与未来之间的历程
J Clin Med. 2023 Mar 11;12(6):2188. doi: 10.3390/jcm12062188.
6
Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients.鲁索替尼治疗期间的感染：免疫功能低下患者环境中基于细胞因子的免疫反应。
J Clin Med. 2023 Jan 11;12(2):578. doi: 10.3390/jcm12020578.
7
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.在单中心真实临床环境中应用RR6预后模型，根据接受鲁索替尼治疗的骨髓纤维化患者的金标准评分预测生存及预后迁移情况。
J Clin Med. 2022 Dec 14;11(24):7418. doi: 10.3390/jcm11247418.
Leuk Lymphoma. 2020 Aug;61(8):1797-1809. doi: 10.1080/10428194.2020.1749606. Epub 2020 Apr 16.
4
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.芦可替尼停药后的情况：218 例骨髓纤维化患者停药原因、疾病阶段的影响和结局。
Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.
5
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.芦可替尼停药后骨髓纤维化的克隆进化与结局
Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.
6
How to define treatment failure for JAK inhibitors.如何定义JAK抑制剂的治疗失败。
Lancet Haematol. 2017 Jul;4(7):e305-e306. doi: 10.1016/S2352-3026(17)30102-3. Epub 2017 Jun 8.
7
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.芦可替尼用于骨髓纤维化患者的长期治疗：来自随机、双盲、安慰剂对照3期COMFORT-I试验的5年更新数据
J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.
8
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
9
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.修订后的骨髓纤维化反应标准：国际工作组-骨髓增生性肿瘤研究和治疗（IWG-MRT）和欧洲白血病网络（ELN）共识报告。
Blood. 2013 Aug 22;122(8):1395-8. doi: 10.1182/blood-2013-03-488098. Epub 2013 Jul 9.